A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 389-395

  Morton, James D ^a   Lee, Hannah Y Y ^a   McDermott, Josh D ^a   Robertson, Lucinda J G ^a   Bickerstaffe, Roy ^a   Jones, Matthew A ^b   Coxon, James M ^b   Abell, Andrew D ^b  

^a LINCOLN UNIVERSITY   (New Zealand)

^b UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CALPAIN; CAT 505; CAT 811; CYTOSKELETON PROTEIN; FILENSIN; GAMMA GLUTAMYLTRANSFERASE; MACROCYCLIC COMPOUND; PLACEBO; SPECTRIN; UNCLASSIFIED DRUG; VIMENTIN; CALPASTATIN; CRYSTALLIN; CYSTEINE PROTEINASE INHIBITOR; GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CATARACT; CELL FREE SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; IMMUNOBLOTTING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCORING SYSTEM; SHEEP; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; LENS; METABOLISM; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CALPAIN; CATARACT; CRYSTALLINS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; LENS, CRYSTALLINE; SHEEP;

MLCS; MLOWN;

EID: 84874542217     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11088     Document Type: Article

References (29)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Org. 2004;82: 844-851.
2. Sasaki K, Sasaki H, Jonasson F, Kojima M, Cheng, HM. Racial differences of lens transparency properties with aging and prevalence of age-related cataract applying a WHO classification system. Ophthalmic Res. 2004;36:332-340.
3. Augusteyn RC. On the growth and internal structure of the human lens. Exp Eye Res. 2010;90:643-654.
4. Bassnett S. On the mechanism of organelle degradation in the vertebrate lens. Exp Eye Res. 2009;88:133-139.
5. Duncan G, Bushell AR. Ion analysis of human cataractous lenses. Exp Eye Res. 1975;20:223-230.
6. 2+-induced protein loss, vimentin cleavage and opacification. Invest Ophthalmol Vis Sci. 2000; 41:2255-2261.
7. Niapour M, Farr C, Minden M, Berger SA. Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression. Blood Cancer J. 2012;2:e51.
8. Yamada KH, Kozlowski DA, Seidl SE, et al. Targeted gene inactivation of calpain-1 suppresses cortical degeneration due to traumatic brain injury and neuronal apoptosis induced by oxidative stress. J Biol Chem. 2012;287:13182-13193.
9. Tompa P, Buzder-Lantos P, Tantos A, et al. On the sequential determinants of calpain cleavage. J Biol Chem. 2004;279: 20775-20785.
10. Pietsch M, Chua KCH, Abell AD. Calpains: attractive targets for the development of synthetic inhibitors. Curr Top Med Chem. 2010;10:270-293.
11. Azuma M, David LL, Shearer TR. Cysteine protease inhibitor E64 reduces rate of formation of selenite cataract in the whole animal. Curr Eye Res. 1991;10:657-666.
12. David LD, Varnum MD, Lampi KJ, Shearer TR. Calpain II in human lens. Invest Ophthalmol Vis Sci. 1989;30:269-275.
13. Robertson LJG, Morton JD, Yamaguchi M, Bickerstaffe R, Shearer TR, Azuma M. Calpain may contribute to hereditary cataract formation in sheep. Invest Ophthalmol Vis Sci. 2005; 46:4634-4640.
14. 2+-overload in ovine lens culture. Vet Ophthalmol. 2008;11: 347-355.
15. Stuart BG, Coxon JM, Morton JD, et al. Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis. J Med Chem. 2011;54:7503-7522.
16. Tyndall JDA, Nall T, Fairlie DP. Proteases universally recognize beta strands in their active sites. Chem Rev. 2005;105:973-999.
17. Abell AD, Coxon JM, Jones MA, et al. Molecular modeling, synthesis and biological evaluation of macrocyclic calpain inhibitors. Angew Chem Int Ed Eng. 2009;48:1455-1458.
18. Azuma M, David LL, Shearer TR. Superior prevention of calcium ionophore cataract by E64d. Biochim Biophys Acta. 1992;1180:215-220.
19. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Nakamura M, Shearer TR. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. Biochim Biophys Acta. 1997;1361:304-312.
20. Sanderson J, Marcantonio JM, Duncan G. Calcium ionophore induced proteolysis and cataract: inhibition by cell permeable calpain antagonists. Biochem Biophys Res Comm. 1996;218: 893-901.
21. Augusteyn RC, Stevens A. Macromolecular structure of the eye lens. Prog Polym Sci. 1998;23:357-413.
22. Jones MA, Morton JD, Coxon JM, et al. Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. Bioorg Med Chem. 2008;16:6911-6923.
23. Lee HYY, Morton JD, Robertson LJG, et al. Evaluation of a novel calpain inhibitor as a treatment for cataract. Clin Experiment Ophthalmol. 2008;36:852-860.
24. Wilson GRS, Morton JD, Palmer DN, et al. The locus for an inherited cataract in sheep maps to ovine chromosome 6. Mol Vis. 2012;18:1384-1394.
25. Nakajima T, Shearer TR, Azuma M. Involvement of calpain 2 in ionomycin-induced cell death in cultured mouse lens epithelial cells. Curr Eye Res. 2011;36:930-936.
26. Robertson LJG, David LL, Riviere MA, Wilmarth PA, Muir MS, Morton JD. Susceptibility of ovine lens a-and bcrystallins to proteolytic cleavage during formation of hereditary cataract. Invest Ophthalmol Vis Sci. 2008;49: 1016-1022.
27. Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol. 2000; 130:441-453.
28. Taylor HR, Keeffe JE. World blindness: a 21st century perspective. Br J Ophthalmol. 2001;85:261-266.
29. Nakajima E, Walkup RD, Ma H, et al. Low activity by the calpain system in primate lenses causes resistance to calciuminduced proteolysis. Exp Eye Res. 2006;83:593-601.